Nutrition Chris Goppelsroeder President & CEO DSM Nutritional Products ROYAL DSM HEALTH NUTRITION MATERIALS
|
|
- Ophelia King
- 5 years ago
- Views:
Transcription
1 Nutrition Chris Goppelsroeder President & CEO DSM Nutritional Products ROYAL DSM HEALTH NUTRITION MATERIALS
2 Safe harbor statement This presentation may contain forward-looking statements with respect to DSM s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this presentation, unless required by law. A more comprehensive discussion of the risk factors affecting DSM s business can be found in the company s latest Annual Report, which can be found on the company's corporate website,
3 DSM: True global leader in Nutrition, active over full value chain Food/Feed value chain Raw Materials 45% of Sales Application based formulations 45% of Sales 10% of Sales Nutritional Ingredients Solutions incl. premix B2C Feed, Food, Pharma, Personal Care producers Retail/end consumer Sales by end-market (%) Sales related to ingredient (%) Sales by region (%) Animal Nutrition & Health Human Nutrition & Health Food Specialties Personal Care & Aroma Intermediates Other 1% Fat soluble vitamins Water soluble vitamins Carotenoids Marine PUFAs Microbial PUFAs Enzymes & cultures Minerals & phosphates Savory / yeast extracts Nutraceutical ingredients Aroma intermediates Other incl. premix EMEA North America Latin America Asia 2016: 5,170m sales - 930m EBITDA 13,260 employees globally Page 1
4 : Underlying EBITDA growth driven by successful acquisitions and good volume growth in Animal Nutrition Nutrition EBITDA bridge ( m) % annual EBITDA growth EBITDA 2010 Price FX Acquisitions Growth/synergies Growth from EBITDA 2015 Vitamin E from acquisitions pre-acquisition ~3 portfolio ~5 ~23% ~17% % annual EBITDA growth on acquisitions 210 Sales ( bn) EBITDA-margin 823 Page 2
5 : Successful acquisitions strengthened the business model, boosted growth & made strong earnings contribution with further potential Human Nutrition Animal Nutrition +10% +7% +2% -2% +5% +11% +25% +45% +4% } meat-scandal +4% Acq. date 17 Acq. Date 17 Acq. 17Acq. 17 date Date Acq. date 17 Acq. Date 17 Acq. date 17 Acq. 17 Date Acq. date Acq. Date Sales EBITDA Growth CAGR EBITDA Acq. date 2017 Growth CAGR Total 225m ~ 400m ~10% Page 3
6 : Organic growth from pre-acquisition portfolio excl. VE driven predominantly by Animal Nutrition Nutrition ANH HNH Net sales ( m) EBITDA ( m) Net sales ( m) Net sales ( m) +5% +9% +9% 0-1% Page 4
7 What made us confident in 2015 on delivering on Strategy 2018 targets? The track record from our broad portfolio excl. VE & FX delivering good sales & EBITDA growth 1 New comprehensive Nutrition Improvement Program accelerating growth & providing a step-up in EBITDA The power of DSM s unique business model further strengthened by acquisitions 2 Page 5 3
8 1 Strategy 2018 is working Organic growth above market in main businesses Nutrition Animal Nutrition Human Nutrition Net sales ( m) Net sales ( m) Net sales ( m) m 6,000 +5% m 4,000 m 4,000 4,000 2,000 4,963 5,169 2,545 +6% 2,778 2,000 +8% 2,269 2,399 1,138 +7% 1,263 2,000 +4% 1,742 1,822 +6% 934 1, H H H H H Market growth: 2-3% Market growth: 2-3% Market growth: 2-3% H Page 6 +% Organic growth %
9 2 Comprehensive Nutrition Improvement Program to enhance performance Strategy 2018 ~5% organic growth per year 1% OWC/Sales reduction per yr ~ 300m capex per year m savings Major impact beyond 2018 Animal Nutrition Integrated Business Planning Product Portfolio Operations Innovation Nutrition EBITDA back to range of 18-20% Human Nutrition Spider in the web ACT (DICI/PIP) Raw materials purchasing More focused portfolio Projects Platforms Fixed cost Staff & Services DSM-wide Savings of m Personal Food Care Specialties For existing and new products Staffs &Support functions Max. throughput Yield & energy and higher speed to market Page 7
10 3 Serving our customers globally via a unique business model relevant in both Animal Nutrition and Human Nutrition GLOBAL PRODUCTS LOCAL SOLUTIONS Complete product portfolio Full value chain player Carotenoids Nutraceuticals & Specialties Minerals Vitamins Omega 3 & 6 Nutritional Lipids Enzymes & Eubiotics LEADING COST POSITION DEMAND CREATION MARKET SEGMENT NEEDS RADICAL INNOVATION ChuKe Feed premixes B2C & B2F Nutritional Ingredients Solutions Applicationbased formulations The best of both worlds: economies of scale AND local customer intimacy Page 8
11 Resulting in above-market growth & EBITDA margins well within range Outperforming Strategy 2018 aspirations Above-market organic growth EBITDA margins 18-20% 8% 25% 6% 4% 2% 5% 6% 20% 15% 10% 5% 18.0% 19.0% 0% 2016 H % 2016 H Page 9
12 Outperforming our Strategy 2018 targets on EBITDA and ROCE growth Outperforming Strategy 2018 targets High single-digit percentage annual Adjusted EBITDA growth High double-digit basis point annual ROCE growth m 1, % 20% % % 10% 5% % 12.0% 12.3% % H H % H H Page 10
13 Confident on further organic growth & EBITDA margin improvement in coming years Organic growth EBITDA margins Animal Nutrition & Health ~5% Nutrition Human Nutrition & Health ~5% Growth Mix Cost Innovation ~20% Food Specialties ~5% Page 11
14
Human Nutrition Jeremy Xu President Human Nutritional & Health ROYAL DSM HEALTH NUTRITION MATERIALS
Human Nutrition Jeremy Xu President Human Nutritional & Health ROYAL DSM HEALTH NUTRITION MATERIALS Safe harbor statement This presentation may contain forward-looking statements with respect to DSM s
More informationDSM Capital Markets Day 2018
DSM Capital Markets Day 2018 Human Nutrition & Health Jeremy Xu President Human Nutrition & Health ROYAL DSM CAPITAL MARKETS DAY LONDON (UK) 20 JUNE 2018 Safe harbor statement This presentation may contain
More informationContinued value growth
Continued value growth Leendert Staal CEO & President DSM Nutritional Products Capital Markets Days 2012 Safe harbor statement This presentation may contain forward-looking statements with respect to DSM
More informationDriving Profitable Growth
Driving Profitable Growth through science-based, sustainable solutions Feike Sijbesma, CEO Royal DSM CONSUMER ANALYST GROUP EUROPE, London 22 March 2016 ROYAL DSM HEALTH NUTRITION MATERIALS Safe harbor
More informationFood Specialties Patrick Niels President DSM Food Specialties ROYAL DSM HEALTH NUTRITION MATERIALS
Food Specialties Patrick Niels President DSM Food Specialties ROYAL DSM HEALTH NUTRITION MATERIALS Safe harbor statement This presentation may contain forward-looking statements with respect to DSM s future
More informationThe acquisition of Fortitech
The acquisition of Fortitech Accelerating DSM s strategy to become a full solutions provider in food ingredient blends Investor Relations 8 November 2012 Overview Fortitech at a glance Acquisition rationale
More informationValue growth in Human Nutrition & Health
Value growth in Human Nutrition & Health Rick Greubel President Human Nutrition & Health US Field Trip September 4, 2014 Safe harbor statement This presentation may contain forward-looking statements with
More informationAn exciting combination in a high growth, high margin Nutrition category. Name of chairman
An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views
More informationContinued value growth in Nutrition
Stephan Tanda, Member of the Managing Board Continued value growth in Nutrition DSM Capital Markets Day 2013 Page Overview Delivering on strategy Update on integration & synergies acquisitions Strategy
More informationDuPont Nutrition & Health Craig Binetti, President
Craig Binetti, President Regulation G The attached charts include company information that does not conform to generally accepted accounting principles (GAAP). Management believes that an analysis of this
More informationA short introduction to DSM (2017) The global science-based company active in health, nutrition and materials
A short introduction to DSM (2017) The global science-based company active in health, nutrition and materials Mission Our purpose is to create brighter lives for people today and generations to come We
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationHarm de Wildt MD TNI
Harm de Wildt MD TNI Nutreco Capital Markets Day Derbyshire, UK 17 September 1 2013 Agenda 1 2 3 Market overview Animal Nutrition Europe Animal Nutrition strategic priorities Application Solution Centres
More informationGELATIN & AKIOLIS. Because every bio-molecule counts. Pol Deturck EVP Chemicals & Organic Specialties
GELATIN & AKIOLIS Because every bio-molecule counts Pol Deturck EVP Chemicals & Organic Specialties Why our bioplatform is promising Dual service provider and highly reliable partner Akiolis, the 3 rd
More informationBank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt. September 14, 2011
Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt Chairman of the Board of Management of Bayer HealthCare AG and Chairman of the Bayer HealthCare Executive Committee
More informationBuilding a new model of sustainable chemistry. Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO
Building a new model of sustainable chemistry Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO Solvay at a glance Acceleration of Solvay s transformation Delivery in a challenging economic
More informationHARNESSING THE POWER OF ALGAE. for Human and Animal Nutrition
HARNESSING THE POWER OF ALGAE for Human and Animal Nutrition MARCEL WUBBOLTS, CTO CORBION 7/14/2018 Corbion: Who we are today 2 Key figures KEY FIGURES (2017) NET SALES BY REGION (2017) NET SALES 891.7mln
More informationBALCHEM CORPORATION. Q Investor Relations Presentation
BALCHEM CORPORATION Q4 2017 Investor Relations Presentation Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life
More informationFood & Beverages Food for a growing world
Food & Beverages Food for a growing world Rasmus von Gottberg, Vice President F&B Marketing, Novozymes Christel Thea Jørgensen, Vice President R&D, Novozymes Jeremy Bentham, Go to Market Director, Cargill
More informationConsumer Wellness in India Growth Ahead
1 Consumer Wellness in India Growth Ahead Indian Health & Wellness industry Valued at over INR 590 bn, growing at CAGR of 18% - 20% p.a. Growth expected to continue. Industry growth being driven by: Increasing
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationADM to Acquire WILD Flavors
ADM to Acquire WILD Flavors Creating a Leading Global Flavors and Specialty-Ingredients Business July 7, 2014 ARCHER DANIELS MIDLAND COMPANY 1 Safe Harbor Statement Some of our statements constitute forward-looking
More informationSüdzucker Group Capital market forum Rhine Neckar
Südzucker Group Capital market forum Rhine Neckar Mannheim, 7 November 2017 Thomas Kölbl (CFO) Südzucker Group, page 1 Südzucker Group at a glance Global operating German food group with long-standing
More informationGlobal Vitamin Market Professional Survey Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Vitamin Market Professional Survey Report 2016 Global Vitamin Market Professional Survey Report 2016 Publication
More informationCLEAN LABEL SOLUTIONS FOR MEAT APPLICATIONS
CLEAN LABEL SOLUTIONS FOR MEAT APPLICATIONS Simplify your label by using potato starch and potato protein 1 Avebe America Inc. 11 Interchange Plaza Suite 11 Cranbury NJ 8512 USA Introduction While cost
More informationSolvay expands its specialty polymers offerings with Ryton PPS acquisition
Solvay expands its specialty polymers offerings with Ryton PPS acquisition Sustained strategic portfolio realignment With Ryton PPS* acquisition, Solvay further strengthens unmatched leadership in Specialty
More informationInvestor Presentation
Investor Presentation Forward Looking Statements The information presented herein may contain projections, predictions, estimates and other forwardlooking statements within the meaning of Section 27A of
More informationCowen Healthcare Conference
Cowen Healthcare Conference Shire plc March 9, 2010 Michael Cola President, Specialty Pharmaceuticals Our purpose We enable people with life-altering conditions to lead better lives 1 THE SAFE HARBOR STATEMENT
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationTable of Contents. 1. About Solvay Solvay at a Glance Group Portfolio Transforming Solvay Solvay s Portfolio Upgrade 7
Solvay Media Kit Table of Contents 1. About Solvay 3 1.1. Solvay at a Glance 4 1.2. Group Portfolio 5 2. Transforming Solvay 6 2.1. Solvay s Portfolio Upgrade 7 3. Organizing for the Future 9 3.1. Why
More informationNestlé Investor Seminar 2008
Nestlé Investor Seminar 2008 Nestlé Nutrition update on Acquisitions Richard Laube CEO Nestlé Nutrition 1 Disclaimer This presentation contains forward looking statements which reflect Management s current
More informationMERCK KGAA, DARMSTADT, GERMANY
MERCK KGAA, DARMSTADT, GERMANY 37TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Belén Garijo, CEO Healthcare Udit Batra, CEO Life Science San Francisco January 7, 2019 Disclaimer Publication of Merck KGaA,
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationConsolidated: Financial Summary
FY2010 First Quarter Financial Results SUZUKI MOTOR CORPORATION 3 August 2010 Consolidated: Financial Summary Page2 FY2010 1Q FY2009 1Q (2010/4-6) (2009/4-6) Change Net sales 656.3 577.1 +79.2 +13.7% Operating
More informationWalgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs
Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion
More informationCLEAN LABEL SOLUTIONS FOR MEAT APPLICATIONS
CLEAN LABEL SOLUTIONS FOR MEAT APPLICATIONS Simplify your label by using potato starch and potato protein 1 Coöperatie AVEBE U.A. P.O. Box 15 964 AA Veendam The Netherlands Introduction While cost effectiveness
More informationGN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference. CEO GN ReSound, Mike van der Wallen September 3, 2008
GN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference CEO GN ReSound, Mike van der Wallen September 3, 2008 GN Store Nord A/S GN GN Store Store Nord Nord Listed Listed company
More informationLetter to Shareholders SEMI-ANNUAL REPORT 2008
Letter to Shareholders SEMI-ANNUAL REPORT 2008 Dear Shareholder You have in your hand the first shareholder letter issued by Nobel Biocare. Thanks to the conversion of Nobel Biocare s bearer shares into
More informationColoplast A/S. Investor Presentation 2005/06
Coloplast A/S Investor Presentation 2005/06 2 Coloplast in brief Coloplast s products and services help patients achieve greater independence from medical challenges in 4 areas, ostomy care, urology &
More informationColoplast A/S. Investor presentation 1H 2005/06
Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound
More informationKAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO
KAPITALMARKNADSDAG 20 SEPTEMBER 2016 Thomas Axelsson, CEO 1 AGENDA 16.10-16.30 VD har ordet Thomas Axelsson, CEO 16.30-16.50 Clinical relevance of time-lapse Dr. Niels B. Ramsing, Business Unit Time-lapse,
More informationDETERMINATION OF MERGER NOTIFICATION M/12/023 -
DETERMINATION OF MERGER NOTIFICATION M/12/023 - DSM/Fortitech Section 21 of the Competition Act 2002 Proposed acquisition by Royal DSM N.V. of sole control of Fortitech, Inc Dated 14 December 2012 Introduction
More informationDIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM
November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf
More informationInvestor Day Lausanne, September 29, Nicholas Rolli Vice President, Investor Relations & Financial Communications
Investor Day Lausanne, September 29, 2016 Nicholas Rolli Vice President, Investor Relations & Financial Communications PMI Investor Relations Mobile Application ("App") / Wi-Fi Access Free app available
More informationSlide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO
Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission
More informationDSM Factbook 2017 ROYAL DSM HEALTH NUTRITION MATERIALS
DSM Factbook 2017 ROYAL DSM HEALTH NUTRITION MATERIALS DSM Investor Relations Contact Dave Huizing Vice President Investor Relations t. +31 45 578 2864 e. dave.huizing@dsm.com Sandra Segers IR Support
More informationConnect with consumers for life. Introducing new MEG-3 Ultra and life sdha Ultra
Connect with consumers for life Introducing new MEG-3 Ultra and life sdha Ultra ega-3s are essential for everyone, every day Omega-3 fatty acids play a critical role in supporting human health across different
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationVITROLIFE AB (PUBL) Pareto Securities Health Care Conference
VITROLIFE AB (PUBL) Pareto Securities Health Care Conference 2018-09-06 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION
More informationFY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009
FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A)
More informationTo be the partner of choice Straumann
To be the partner of choice Straumann Gilbert Achermann, CEO Helvea Swiss Equities Conference 11 January 2008, Bad Ragaz Table of contents 1. A snapshot of Straumann 2. Financials 3. Markets and opportunities
More informationElekta Innovation and Growth. ESTRO 2012 Capital Markets Presentation
Elekta Innovation and Growth ESTRO 2012 Capital Markets Presentation 15.00 Introduction Partner in cancer care Growth Tomas Puusepp President and CEO 15.30 Patient-focused development Cancer care solutions
More informationGlobal Specialty Food Ingredients Market: Industry Analysis & Outlook ( )
Industry Research by Koncept Analytics Global Specialty Food Ingredients Market: Industry Analysis & Outlook ----------------------------------------- (2017-2021) January 2018 Global Specialty Food Ingredients
More information1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationSlide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO
Slide 1 Lars Fruergaard Jørgensen President and CEO Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the company
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationVITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar
VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar 2018-08-16 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION A Swedish
More informationELICA 2012 Q3 RESULTS. November 14,
ELICA ELICA 1 Q3 12 Highligths Negative market demand, showing better trend compared to previous quarters Group sales over performing in all major markets Cost reduction efforts and continued product innovation
More informationMiFOOD2017. Grand Rapids April 18 th Daragh Maccabee SVP Procurement & Dairy Economics Glanbia Nutritionals
MiFOOD2017 Grand Rapids April 18 th 2017 Daragh Maccabee SVP Procurement & Dairy Economics Glanbia Nutritionals OUR BUSINESSES TODAY MARKET CAP 5BN EMPLOYEES 6,200 GLANBIA PERFORMANCE NUTRITION GLANBIA
More informationCorporate Presentation
Corporate Presentation January 2019 2018 Chembio. All Rights Reserved. # 2019 Chembio. All Rights Reserved. Page 1 Safe Harbor Statement Statements contained herein that are not historical facts are forward-looking
More informationA GLOBAL LEADER IN PERSONALIZED NUTRITION
A GLOBAL LEADER IN PERSONALIZED NUTRITION Forward Looking Statements Management will make forward-looking statements during this presentation. Actual results could differ from those projected in such forward-looking
More informationWHAT WE DO OLEON IN SHORT 2
OLEON IN SHORT WHAT WE DO OLEON IN SHORT 2 OLEOCHEMISTRY triglycerides BASE oleochemicals fatty acids glycerine monopropylene glycol dimer acids ketones, technical oils & other specialty chemicals oleochemical
More informationAcasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019 Planned Enrollment targets achieved in both TRILOGY studies with over 74% of patients randomized at more than 150 clinical sites
More informationGlobal Nutraceuticals Market
Published on NOVONOUS (https://www.novonous.com) Home > Global Nutraceuticals Market 2016-2020 Global Nutraceuticals Market 2016-2020 Publication ID: NOV1016004 Publication Date: October 14, 2016 Pages:
More informationMerrill Lynch conference. Matthew Emmens, CEO Shire plc September 20, 2007
Merrill Lynch conference Matthew Emmens, CEO Shire plc September 20, 2007 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical
More informationDesigning a Smoke-Free Future
Designing a Smoke-Free Future Morgan Stanley Global Consumer & Retail Conference New York, November 14, 2017 Jacek Olczak Chief Financial Officer Martin King President, Asia Region Forward-Looking and
More informationMerrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004
Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004 Disclaimer 2 This presentation contains forward-looking statements, i.e., current estimates or expectations
More informationDentivera Milling Discs. Powering the Digital Revolution. Supported by Solvay. Make METAL-FREE Possible with Ultaire AKP. Dental Lab Advantages
Powering the Digital Revolution Dental Lab Advantages Increasingly, labs are moving toward digital dentistry. Ultaire AKP is custom-formulated to take full advantage of the digital workflow so you can
More informationGlobal Vitamin Ingredients Market
Global Vitamin Ingredients Market 2016-2020 Global Vitamin Ingredients Market 2016-2020 BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years.
More informationPassion for progress, care for people
Passion for progress, care for people SPIL Analyst Meeting 25 th April, 2008 DISCLAIMER ACTUAL RESULTS / OUTCOMES MAY BE DIFFERENT FROM ANY FORWARD LOOKING STATEMENTS / VIEWS / ESTIMATES EXPRESSED HEREIN.
More informationDeveloping Food Derived Compounds for Health The Innovation Process
Developing Food Derived Compounds for Health The Innovation Process Plants for Health Danish Food and Drink Federation June 15th, 2011 Kevin Prudence Innovation Project Manager DSM Nutrition a healthy
More informationValue creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO
Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,
More informationCompany presentation. SEB Nordic Seminar Bella Sky, Copenhagen. Carsten Hellmann, President & CEO 9 January 2018
Company presentation SEB Nordic Seminar Bella Sky, Copenhagen Carsten Hellmann, President & CEO 9 January 2018 Allergy: a global disease with a large unmet need >500 million people affected by allergic
More informationFIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO
FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO DISCLAIMER This document contains certain forward-looking information that is subject toa number of factors that may influence the accuracy of
More information1Q2005. Hera Group presentation
1Q2005 Hera Group presentation 1 Y2005 has been characterized by a stream of achievements: Corporate Governance A new BoD was appointed in April. Further penetration of the Hera Gas market: 1,500 new clients
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationEurope Ginseng Market Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Europe Ginseng Market Report 2016 Europe Ginseng Market Report 2016 Publication ID: QYR12167206 Publication December
More informationInvestor Day LA&C Region Lausanne, September 29, Jeanne Pollès President, Latin America & Canada Region
Investor Day LA&C Region Lausanne, September 29, 2016 Jeanne Pollès President, Latin America & Canada Region Agenda Regional Overview and Performance Regional Strategies Key Markets Conclusion 2 LA&C Regional
More informationJefferies Healthcare Conference
Jefferies Healthcare Conference Jean-Marc BOTHY - CSO June 8, 2017 2017 IBA SA Disclaimer This presentation may contain forward-looking statements concerning industry outlook, including growth drivers;
More informationMyriad Genetics Corporate Presentation 06/13/2018
Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today
More informationSlide 1. Investor presentation. Copenhagen 1 November 2018
Slide 1 Investor presentation Copenhagen 1 November 2018 Manato Shirley Ohara, Adelia Stewart diagnosed has type with 2 diabetes type 1 diabetes Kanagawa, New Orleans, Japan Louisiana, US Slide 2 Highlights
More informationTelekom Austria Group Results for the 1st Quarter May 27, 2003
Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those
More informationWelcome to the Full -Year Results Press Conference
Welcome to the Full -Year Results Press Conference Disclamer This presentation contains forward looking statements which reflect Management s current views and estimates. The forward looking statements
More informationThird-quarter results 2013
Third-quarter results 213 Fornebu, 6 November 213 Øyvind Eriksen and Leif Borge Agenda 213 Introduction Øyvind Eriksen Executive chairman Financials Leif Borge President & CFO Q&A Q&A session Øyvind Eriksen
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationNatus Medical Incorporated. Jeffries Global Healthcare CONFERENCE Tuesday June 6, 2017
Natus Medical Incorporated Jeffries Global Healthcare CONFERENCE Tuesday June 6, 2017 Forward-Looking Statements This presentation contains forward-looking statements including statements regarding our
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationStraumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010
Media release Straumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010 Growth driven by implant volumes, lifted by Bone Level implant range and Roxolid Third quarter (+3%
More informationNomura Healthcare Conference
Nomura Healthcare Conference Sebastien Martel Head of Investor Relations London, July 1st, 2011 Forward Looking Statements 2 This presentation contains forward-looking statements as defined in the Private
More information4.2. DSM, having acquired Martek, is now the world s leading manufacturer of microbiallyproduced
4.1 4.2 DSM, having acquired Martek, is now the world s leading manufacturer of microbiallyproduced DHA and ARA. DHA and ARA are two fatty acids that are important for proper infant nutrition due to their
More informationBalchem Corporation Investor Relations
Balchem Corporation Investor Relations May 2017 Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life on the planet.
More informationWelcome to the Nine-Month Sales Conference
Welcome to the Nine-Month Sales Conference Nine-Month Sales Conference Paul Bulcke Nestlé CEO Nine-Month Sales Conference Wan Ling Martello Chief Financial Officer Disclaimer This presentation contains
More informationGlobal Chymosin Market Research Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Chymosin Market Research Report 2016 Global Chymosin Market Research Report 2016 Publication ID: QYR101602046
More informationGROWTH NOW! Franck Riboud
GROWTH NOW! Franck Riboud June 15 h, 2010 Disclaimer This document contains certain forward-looking statements concerning DANONE. Although DANONE believes its expectations are based on reasonable assumptions,
More informationWilliam Demant. Jefferies Healthcare Conf. Nov Søren B. Andersson, VP Investor Relations
William Demant Jefferies Healthcare Conf. Nov. 2017 Søren B. Andersson, VP Investor Relations Agenda General update Key take-aways from November Interim Statement Hearing Devices Outlook 2017 Q&A 2 General
More informationMedSurg: Endoscopy Presentation for the Investment Community at DDW. Art Butcher Senior Vice President and President, Endoscopy
MedSurg: Endoscopy Presentation for the Investment Community at DDW Art Butcher Senior Vice President and President, Endoscopy Safe Harbor for Forward-Looking Statements This presentation contains forward-looking
More informationLaunch of a new binders : Leveraging innovation to an economic advantage.
Launch of a new binders : Leveraging innovation to an economic advantage. Maximizing customers benefit by reducing cost of change Roberta Colombo & Thierry Baert The cost of innovation for materials. The
More informationBest-in-Class and GS1 Digital. Steve Bratt, GS1 CTO & President, Standards Development
Best-in-Class and GS1 Digital Steve Bratt, GS1 CTO & President, Standards Development 1 Making GS1 Standards Development Best-in- Class http://www.gs1.org/gsmp/best_in_class 2 Best in Class Standards Development
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More information